Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma

Annals of Hematology

Volumn 85, Issue 6, 2006, Pages 374-380

  Niitsu, Nozomi ^a,b   Okamoto, Masataka ^b   Aoki, Sadao ^b   Okumura, Hirokazu ^b   Yoshino, Tadashi ^b   Miura, Ikuo ^b   Hirano, Masami ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Adult Lymphoma Treatment Study Group: ALTSG   (Japan)

Author keywords

Aggressive lymphoma; CyclOBEAP; Diffuse large B cell lymphoma; International prognostic index

Indexed keywords

BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; FEMALE; FOLLICULAR LYMPHOMA; HEART DISEASE; HUMAN; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SKIN DISEASE; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME; VINCRISTINE;

EID: 33645841342     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0080-x     Document Type: Article

References (21)

1. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244
2. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
3. Cox DR (1972) Regression models and life tables. J Stat Soc Br 34:187-202
4. Elias L, Portlock CS, Rosenberg SA (1978) Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer 42:1705-1710
5. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
6. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, France
7. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
8. Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602
9. Linch DC, Smith P, Hancock BW et al (2000) A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 11:87-90
10. Longo DL, DeVita VT Jr, Duffey PL et al (1991) Superiority of Pro-MACE-CytaBOM over Pro-MACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized study. J Clin Oncol 9:25-38
11. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170
12. Niitsu N, Okamoto M, Kuraishi Y, Nakamura S, Kodama F, Hirano M (2000) CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: A pilot study. The Adult Lymphoma Treatment Study Group (ALTSG). Eur J Haematol 65:188-194
13. Non-Hodgkin's lymphoma Classification Project (1982) National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma: summary and description of a working formulation for clinical usage. Cancer 49:2112-2135
14. Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641
15. Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633
16. Pfreundschuh M, Trumper L, Ma D et al (2004) Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-early stopping after the first interim analysis. J Clin Oncol (Abstracts) 22:#6500
17. Shipp MA: International non-Hodgkin's lymphoma prognostic factors project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
18. Tilly H, Lepage E, Coiffier B et al (2003) Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289
19. Travis LB, Curtis RE, Stovall M et al (1994) Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457
20. Wilcoxon F (1945) Individual comparisons by ranking methods. Biom Bull 1:80-83
21. Wolf M, Matthews JP, Stone J, Cooper IA, Robertson TI, Fox RM (1997) Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Ann Oncol 8:71-75